A
Anbio Biotechnology
NASDAQ:NNNN
Anbio Biotechnology
NASDAQ:NNNN
Price:
22.54
USD
2.88%
Market Closed
Market Cap:
$3.2B
Relative Value
There is not enough data to reliably calculate the relative value of NNNN.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
NNNN
Relative Value
Base Case
Not Available
A
Multiples Across Competitors
NNNN Competitors Multiples
Anbio Biotechnology Competitors
Anbio Biotechnology Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| DE |
A
|
Anbio Biotechnology
NASDAQ:NNNN
|
3.2B USD | 0 | 0 | 0 | 0 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
398.4B USD | 6.5 | 95.2 | 15.6 | 21.7 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
198.2B USD | 5.4 | 25.7 | 14.8 | 14.8 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
180.2B USD | 6.1 | 21.2 | 13.2 | 16.3 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
121.4B USD | 10.1 | 30.7 | 23.2 | 24.2 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
78.9B USD | 5.5 | 17.5 | 13 | 14.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
68B AUD | 3.1 | 34.5 | 11.4 | 14.3 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 | |
| NL |
|
argenx SE
XBRU:ARGX
|
37.9B EUR | 10.8 | 34.5 | 37.4 | 38.2 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
